Cassava Sciences down another 3% as SEC provides update on simufilam probe
2024-07-01
ablokhin The SEC has provided Cassava Sciences (NASDAQ:SAVA) with additional information from an ongoing investigation of the agency’s phase 2b study of Alzheimer’s candidate simufilam. While the company did not provide details about that information in a Monday SEC filing, it did say it has formed an internal committee ofContinue Reading
